Researchers Identify Key Weakness in Pancreatic Cancer, Opening New Treatment Avenues
Researchers at The Wistar Institute and ChristianaCare’s Helen F. Graham Cancer Center & Research Institute have discovered a significant vulnerability in pancreatic cancer cells. The study, published in the Proceedings of the National Academy of Sciences, reveals that damaged mitochondria within cancer cells release double-stranded RNA, triggering an inflammatory response that the tumors rely on for survival. By blocking this inflammatory process, the cancer cells die, offering a potential new therapeutic target. The research highlights the TLR3/TRAF6 signaling pathway as a promising focus for treatment, marking the first time this mechanism has been linked to cancer development. This discovery is particularly crucial given the limited treatment options and poor prognosis associated with pancreatic cancer. 
